Clinical and economic benefits of advanced microplegia delivery system in cardiac surgery: evidence from 250 hospitals.
Determine the impact of a second generation microplegia delivery system (MPS2) compared with traditional cardioplegia. Materials & methods: Multivariable difference-in-differences analysis using fixed effects was performed for each outcome: adverse event (AE) composite, total visit cost, medication cost, length of stay (LOS) and intensive care unit (ICU) days. A 2.25% absolute risk reduction in AE composite was found with MPS2 compared with traditional cardioplegia, which equates to relative risk reduction of 5.25%. Significant reductions in LOS and ICU days (0.1 α level). Per case reduction of US$1231 total visit and US$192 medication costs were found in MPS2 hospitals. For hospitals with MPS2, significant reductions were seen in AEs, LOS and ICU days, which lead to reductions in total visit and medication costs.